Decheng Capital LLC Sells 10,000 Shares of Krystal Biotech, Inc. $KRYS

Decheng Capital LLC lowered its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 57.8% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,300 shares of the company’s stock after selling 10,000 shares during the period. Krystal Biotech accounts for 0.3% of Decheng Capital LLC’s holdings, making the stock its 13th largest holding. Decheng Capital LLC’s holdings in Krystal Biotech were worth $1,886,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of KRYS. Avoro Capital Advisors LLC lifted its stake in shares of Krystal Biotech by 4.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,888,888 shares of the company’s stock valued at $712,226,000 after acquiring an additional 111,111 shares during the last quarter. State Street Corp boosted its holdings in shares of Krystal Biotech by 10.5% during the 2nd quarter. State Street Corp now owns 1,355,346 shares of the company’s stock valued at $186,306,000 after acquiring an additional 128,639 shares in the last quarter. Soleus Capital Management L.P. grew its position in Krystal Biotech by 108.9% during the 2nd quarter. Soleus Capital Management L.P. now owns 922,958 shares of the company’s stock worth $126,870,000 after acquiring an additional 481,200 shares during the last quarter. Dimensional Fund Advisors LP grew its position in Krystal Biotech by 5.5% during the 3rd quarter. Dimensional Fund Advisors LP now owns 533,964 shares of the company’s stock worth $94,261,000 after acquiring an additional 28,075 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Krystal Biotech by 13.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 529,955 shares of the company’s stock worth $130,656,000 after purchasing an additional 62,897 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Wall Street Analyst Weigh In

KRYS has been the subject of several research reports. TD Cowen increased their target price on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research report on Thursday, June 18th. Wolfe Research assumed coverage on Krystal Biotech in a report on Friday, March 27th. They set a “peer perform” rating on the stock. Citigroup upped their price objective on Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Jefferies Financial Group reiterated a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a report on Monday, July 13th. Finally, Weiss Ratings downgraded shares of Krystal Biotech from a “buy (b)” rating to a “buy (b-)” rating in a research report on Wednesday, July 1st. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $360.67.

Insider Transactions at Krystal Biotech

In related news, EVP John Charles Thomas sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $347.27, for a total value of $347,270.00. Following the sale, the executive vice president directly owned 1,000 shares in the company, valued at $347,270. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares in the company, valued at $424,623,337.05. The trade was a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 26,642 shares of company stock valued at $8,243,923 over the last 90 days. 13.10% of the stock is owned by corporate insiders.

Krystal Biotech Stock Down 0.7%

NASDAQ KRYS opened at $336.80 on Thursday. The company has a market capitalization of $9.93 billion, a price-to-earnings ratio of 45.03 and a beta of 0.50. Krystal Biotech, Inc. has a twelve month low of $130.50 and a twelve month high of $382.54. The stock has a fifty day simple moving average of $332.97 and a 200 day simple moving average of $291.66.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The firm had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. Research analysts expect that Krystal Biotech, Inc. will post 7.31 earnings per share for the current fiscal year.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.